Zurcher Kantonalbank Zurich Cantonalbank Has $11.70 Million Holdings in Moderna, Inc. (NASDAQ:MRNA)

Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 75.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 117,636 shares of the company’s stock after buying an additional 50,504 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Moderna were worth $11,699,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. First Pacific Financial acquired a new position in shares of Moderna during the third quarter worth approximately $27,000. ICA Group Wealth Management LLC acquired a new position in shares of Moderna during the fourth quarter worth approximately $27,000. Arlington Trust Co LLC lifted its holdings in shares of Moderna by 4,833.3% during the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after buying an additional 290 shares during the last quarter. Stonebridge Capital Advisors LLC lifted its holdings in shares of Moderna by 79.1% during the first quarter. Stonebridge Capital Advisors LLC now owns 283 shares of the company’s stock worth $49,000 after buying an additional 125 shares during the last quarter. Finally, Ancora Advisors LLC lifted its holdings in shares of Moderna by 41.2% during the first quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock worth $51,000 after buying an additional 96 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Shannon Thyme Klinger sold 670 shares of the company’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $63,361.90. Following the transaction, the insider now owns 8,557 shares of the company’s stock, valued at $809,235.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Moderna news, CFO James M. Mock sold 647 shares of the stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $61,186.79. Following the transaction, the chief financial officer now owns 4,300 shares of the company’s stock, valued at $406,651. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Shannon Thyme Klinger sold 670 shares of the stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $63,361.90. Following the completion of the transaction, the insider now directly owns 8,557 shares in the company, valued at approximately $809,235.49. The disclosure for this sale can be found here. Insiders have sold 109,954 shares of company stock valued at $11,533,976 over the last 90 days. 15.70% of the stock is owned by company insiders.

Moderna Trading Down 0.6 %

Shares of MRNA stock opened at $101.41 on Friday. The stock’s fifty day moving average is $100.63 and its 200-day moving average is $93.64. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $144.43.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, topping the consensus estimate of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The company had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.53 billion. During the same quarter in the prior year, the business earned $3.61 earnings per share. The business’s revenue for the quarter was down 44.9% on a year-over-year basis. As a group, sell-side analysts forecast that Moderna, Inc. will post -7.51 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently issued reports on MRNA. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Thursday, April 11th. Royal Bank of Canada restated an “outperform” rating and set a $125.00 price objective on shares of Moderna in a research report on Thursday, March 28th. Oppenheimer upgraded Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective on the stock in a research report on Tuesday, January 2nd. Jefferies Financial Group restated a “buy” rating and set a $125.00 price objective on shares of Moderna in a research report on Tuesday, April 9th. Finally, HSBC reiterated a “reduce” rating and issued a $86.00 price target (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $126.49.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.